Meghna Alimchandani

United States Food and Drug Administration

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021”.

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

MMWR Morbidity and Mortality Weekly Report(2021)10.15585/mmwr.mm7032e4

N/A

0DataRank · unranked

215 citations

Stephen C. Hadler, Danielle Moulia, Tom T. Shimabukuro, John R. Su, Naomi K. Tepper +17 more

COVID-19 Vaccine Safety First Year Findings in Adolescents

PEDIATRICS(2023)10.1542/peds.2022-060295

N/A

0DataRank · unranked

16 citations

Anne M. Hause, Tanya R. Myers, John R. Su, Paige Marquez, Bicheng Zhang +13 more